Navigation Links
Vion Pharmaceuticals Announces FDA Conclusion
Date:12/30/2009

NEW HAVEN, Conn., Dec. 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM). The FDA raised concerns with the HOVON trial design as submitted regarding the primary endpoint and study regimen. The modifications requested by the FDA would require a new Phase III trial at significant additional time and expense.

Vion will evaluate whether to file another SPA for an alternative randomized Phase III trial within the next two weeks. In this context, the SPA process is intended to evaluate a Phase III protocol whose data will form the primary basis for an efficacy claim. The Phase III randomized trial in acute myeloid leukemia ("AML") is in response to the FDA's complete response letter to Vion's New Drug Application for Onrigin(TM) requiring that a randomized trial be conducted to support the approval of Onrigin(TM) for the treatment of AML.

On December 17, 2009, Vion filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court in the District of Delaware. Vion has retained the services of Roth Capital Partners, LLC to assist with the sale of the Company and/or its key assets during the Chapter 11 proceeding. Additional information about Vion's Chapter 11 case is available on the website of the court's claims agent at www.delclaims.com.

For additional information on Vion and its product development pr
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), ... and commercialization of novel bile acid therapeutics to treat ... announced that Mark Pruzanski , MD, ... Deutsche Bank Securities 38th Annual Health Care Conference in ... 2013 at 4:10 p.m. ET. About Intercept ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, ... announced today that it will present new results ... an industry conference sponsored by the PML Consortium ... Idec).  JC polyomavirus (JCV) is the causative agent ... tyrosine kinase inhibitor in an extended release formulation, ...
(Date:5/23/2013)... 23, 2013  PAREXEL International Corporation (NASDAQ: ... at the Jefferies Healthcare Conference in New York.  ... Chief Financial Officer, will be making a presentation on ... Monday, June 3, 2013. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2
... March 20, 2012  OriGene Technologies today announced the ... and extensively validated monoclonal antibodies under the UltraMAB™ ... antibodies which are exclusively developed by OriGene for ... products available on the market that have been ...
... YORK, March 20, 2012 Reportlinker.com announces that ... its catalogue: The Outlook ... http://www.reportlinker.com/p0192645/The-Outlook-for-Medical-Devices-in-Central-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility The ... total market of 303 million people and a ...
Cached Medicine Technology:OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies 2The Outlook for Medical Devices in Central Asia 2The Outlook for Medical Devices in Central Asia 3The Outlook for Medical Devices in Central Asia 4
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... Susquehanna Health is now a ... training course for adolescents age 11 and up. ... Dr. Patricia Keener after a colleague’s toddler choked to ... who didn’t know how to provide first aid. Safe ... medical basis that aims to reduce the number of ...
(Date:5/23/2013)... next generation genomic analysis to determine that some of ... origins, which may help in predicting cancer progression. The ... Research . , "This is the first study to ... Gleason patterns in the same tumor allowing us to ... M.D., Mayo Clinic pathologist and one of the authors ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
Breaking Medicine News(10 mins):Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... TORONTO, Oct. 26 HearAtLast, Inc., (Pink,Sheets: HRAL) announced ... the company. HearAtLast, Inc. The research report,provides an investment ... summary of the Company as an investment opportunity, an,overview ... a,discussion of the company,s industry. To read the report ...
... November 8 and 9, 2007, PENSACOLA, Fla., ... excited to be a major sponsor for this ... leaders in,healthcare, the Department of Defense, Veterans Administration, ... find solutions,for strategic health intelligence. This summit represents ...
... Actively ... Engaged In Community Service, CHICAGO, Oct. 26 Banco Popular ... leading U.S.,Small Business Administration Lender, today announced its nationwide,participation in Make ... taken part of this special national day of,helping others for six ...
... small but revealing study from the Johns Hopkins Childrens ... physical, emotional and psychological functioning and well-being in children ... the children with some of the most severe bladder ... possibility is that children with such conditions manage to ...
... IND proposes a randomized Phase,III pivotal clinical trial ... versus BSC alone for the treatment of patients ... stomach who,have failed adjuvant or 1st or 2nd ... and will direct the clinical development program. The,Company ...
... Oct. 26 Applying quality initiatives,to sales and ... "Managing Quality to Drive Growth," the third quarter,conference ... executives from 20 leading companies discussed hot-button issues,around ... into,sales, marketing and new product development. "We ...
Cached Medicine News:Health News:Harbinger Research Initiates Coverage on HearAtLast 2Health News:Cogon Systems Supports the Pensacola Bay Area Chamber of Commerce with the Strategic Health Intelligence Summit 2Health News:Banco Popular Commits To Make A Difference Day 2007 2Health News:Banco Popular Commits To Make A Difference Day 2007 3Health News:Banco Popular Commits To Make A Difference Day 2007 4Health News:Quality-of-life yardstick needed for children with serious urologic conditions, Hopkins study shows 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Tailor Quality Initiatives to Improve Sales, Marketing & New Product Development 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: